By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Optivia Biotechnology today announced it has been awarded a $1.9 million Phase II Small Business Innovation Research grant to "determine the precise mechanisms that underlie certain drug-to-drug interactions," in an effort to improve medication safety.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Researchers link genetic links between education and smoking and longevity.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.